The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis

Phase 3 Terminated 22 enrolled Mayo Clinic National Heart, Lung, and Blood Institute (NHLBI) · collab National Institute on Aging (NIA) · collab Novartis · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

We will study the hypothesis that long-term Tekturna treatment will improve endothelial function and the production and function of endothelial progenitor cells (EPCs) in patients with early atherosclerosis. Specifically, long-term Tekturna treatment will increase the Reactive Hyperemia Peripheral Arterial Tonometry indexes and increase the numbers and the function of circulating endothelial progenitor cells, compared to placebo, in association with a reduction in inflammation and oxidative stress.

Timeline

Start: 2010-02
Primary completion: 2011-12
Completion: 2011-12

Publications

Flammer AJ, Gossl M, Li J, Reriani M, Shonyo S, Loeffler D, Herrmann J, Lerman LO, Lerman A. Renin inhibition with aliskiren lowers circulating endothelial progenitor cells in patients with early atherosclerosis. J Hypertens. 2013 Mar;31(3):632-5. doi: 10.1097/HJH.0b013e32835c6d2d. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aliskiren	Small molecule	150 mg	—

Indications

No indication recorded.